Dasatinib-letrozole gets split verdict.

Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer compared with letrozole alone, the clinical benefit was the same for both groups.